Developmental XXXX study in @entity35 treated with the anticonvulsant, @entity73207 .

@entity410 @entity137 @entity458 @entity600 @entity1017 @entity73207 @entity35 @entity204 @entity65 @entity2055
The developmental @entity137 of the anticonvulsant compound, @entity73207 , was investigated in @entity35 administered oral doses of 0, 15, 60, 120, 180, or 240 mg/kg on days 6 through 15 of gestation. An untreated control group and a vehicle control group pair-fed to the high dose group were included. Maternal and fetal parameters were evaluated on day 21 of gestation. Fetuses were examined for external, @entity600 and variations. @entity204 occurred at 180 and 240 mg/kg. Dose-dependent decreases in body weight, food consumption, and water consumption were observed at 60 mg/kg and above. Body @entity1017 during treatment was similar in the pair-fed and 240 mg/kg groups. Dose-related CNS signs ( @entity458 , @entity2055 , prostration, and/or @entity410 ) were observed at 60 mg/kg and above. Decreased numbers of live fetuses and increased postimplantation loss were observed in a dose-related manner at 120, 180, and 240 mg/kg while no changes occurred in pair-fed controls. Fetal body weights and placental weights were decreased in pair-fed controls and in the 120, 180, and 240 mg/kg groups. The percent fetuses per litter, and the percent litters with @entity600 , were significantly increased at 120, 180, and 240 mg/kg compared with vehicle and pair-fed controls. Dose-related @entity65 , specifically of the aortic arch (interrupted, stenotic, extra vessel), were apparent at 120 mg/kg and above. The incidence of skeletal variations was increased at 120 mg/kg and above.(ABSTRACT TRUNCATED AT 250 WORDS)
